- Home
- CMPO vs RCUS Comparison
CMPO vs RCUS Comparison
Compare CMPO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- RCUS
- Stock Information
- Founded
- CMPO 2000
- RCUS 2015
- Country
- CMPO United States
- RCUS United States
- Employees
- CMPO N/A
- RCUS N/A
- Industry
- CMPO Finance: Consumer Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- RCUS Health Care
- Exchange
- CMPO Nasdaq
- RCUS Nasdaq
- Market Cap
- CMPO 1.2B
- RCUS 1.2B
- IPO Year
- CMPO N/A
- RCUS 2018
- Fundamental
- Price
- CMPO $18.50
- RCUS $12.20
- Analyst Decision
- CMPO Strong Buy
- RCUS Buy
- Analyst Count
- CMPO 6
- RCUS 8
- Target Price
- CMPO $17.67
- RCUS $20.71
- AVG Volume (30 Days)
- CMPO 1.2M
- RCUS 772.4K
- Earning Date
- CMPO 08-07-2025
- RCUS 11-05-2025
- Dividend Yield
- CMPO N/A
- RCUS N/A
- EPS Growth
- CMPO N/A
- RCUS N/A
- EPS
- CMPO N/A
- RCUS N/A
- Revenue
- CMPO $267,817,999.00
- RCUS $262,000,000.00
- Revenue This Year
- CMPO $9.93
- RCUS N/A
- Revenue Next Year
- CMPO $8.49
- RCUS N/A
- P/E Ratio
- CMPO N/A
- RCUS N/A
- Revenue Growth
- CMPO N/A
- RCUS 6.07
- 52 Week Low
- CMPO $9.24
- RCUS $6.50
- 52 Week High
- CMPO $20.14
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CMPO 56.22
- RCUS 75.43
- Support Level
- CMPO $18.52
- RCUS $10.40
- Resistance Level
- CMPO $19.18
- RCUS $11.84
- Average True Range (ATR)
- CMPO 0.67
- RCUS 0.54
- MACD
- CMPO -0.24
- RCUS 0.16
- Stochastic Oscillator
- CMPO 39.03
- RCUS 98.35
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.